Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acyclovir Prophylaxis in HIV-1/HSV-2 Co-Infected Individuals
NCT00405821Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2006
- Primary completion
- Oct 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) and genital herpes comparing Acyclovir Arm with Placebo Arm (2 arms). Primary endpoint: Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis) at 2 years. Started Nov 2006; status: completed.
02
Drugs
aciclovir
03
Conditions
human immunodeficiency virus infection (HIV)genital herpes
Beyond the preview
Go deeper on NCT00405821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405821.